News

Interim results from the PRISM population extension cohort found that 4D-150 was well tolerated and reduced the mean annualized anti-VEGF injection rate.

At 24 weeks, the oral therapy was well-tolerated and the safety profile remained in line with previous brepocitinib studies and the pharmacological class.

One-year 1/2 data examines the safety and efficacy of OCU400 gene therapy for the treatment of retinitis pigmentosa.

New data from RHONE-X at ASRS suggest over 90% of DME patients treated with faricimab (Vabysmo) were DME-free at 4 years, with nearly 80% on 3-4 month dosing intervals.

These data highlight results on efficacy, quality of life, and tolerability of DMF within routine clinical practice among those with plaque psoriasis.

A new study found individuals with depression and anxiety have a high prevalence of medical debt.

An ASRS 2024 study found no significant difference in post-injection endophthalmitis rates between using nonsterile gloves and not using gloves for anti-VEGF injections.

These findings suggest that those with atopic dermatitis exacerbations may need to limit their oral corticosteroid duration for the purposes of limiting AEs.

Topline Phase 2b/3 results show high- and low-dose MCO-010 treatment improved BCVA compared to control through 100 weeks.

A single Ixo-vec injection showed up to a 95% reduction in annualized anti-VEGF injections, according to first-time 26-week results from the Phase 2 LUNA study.

Pegcetacoplan for 36 months led to fewer absolute scotomatous points on microperimetry than delayed treatment, suggesting its efficacy in preserving vision.

RGX-314 produced by the NAVXpress platform process showed a similar clinical profile to the adherent cell culture process in this Phase 2 pharmacodynamic study.

The XTEND-Kids phase 3 trial shows efanesoctocog alfa’s safety and efficacy in children with severe hemophilia A, reducing bleeds with once-weekly dosing.

In this Q&A interview, Stein Gold discusses new phase 3 findings regarding ruxolitinib cream 1.5% for patients 2 to 11 years old with atopic dermatitis.

Younger adults (aged 20 – 40 years) with OSA were 3 times more likely to experience any type of CVD event than those without OSA.

The novel potassium-competitive acid blocker now boasts 3 FDA approvals across erosive and non-erosive GERD, expanding the treatment armamentarium for patients and clinicians.

Phase 2 data from the ARCHER study shows a protective effect of ANX007 on visual acuity and anatomical measures in the central macula in patients with GA.

Vonoprazan (Voquezna), the first major innovation in GERD treatment in more than 30 years, is now FDA-approved for both erosive and non-erosive GERD.

Adalimumab-adbm is now available at a 92% discount from the reference drug list price through GoodRx.

OTX-TKI remained generally well-tolerated in patients with moderately severe to severe NPDR across 48 weeks of the Phase 1 trial.

Announced on July 18, 2024, the FDA approval for heartburn relief associated with non-erosive GERD is based on the phase 3 PHALCON-NERD-301 trial.

Katherine Talcott, MD describes a posthoc analysis of the GATHER trials showing how imaging biomarkers of photoreceptor structure predict GA growth.

Veeral Sheth, MD describes an assessment of the need for supplemental injection use after EYP-1901 for wet AMD.

The PRISM trial's 24-week data show 4D-150 reduced anti-VEGF injection rates by 89% in wet AMD, with 77% of patients injection-free at 24 weeks.

These data suggest that risk of developing psoriatic arthritis among patients with different variants of psoriasis vary based on race and sex as well.

A new study showed the efficiency and speed of a new AI model for a heart scan.

The cross-sectional analysis found Medicaid nonexpansion status, fibrosis, and sobriety restrictions negatively impacted annual rates of DAA prescription fills.

A phase 2 trial showed cendakimab, an IL-13 inhibitor, reduced Eczema Area and Severity Index scores in moderate to severe atopic dermatitis patients.